Business Context and Reporting Period
This Form 8-K Current Report was filed by BlueLinx Holdings Inc. on October 28, 2020. The filing discloses the entry into a material definitive agreement regarding the potential issuance and sale of the company's common stock.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial figure disclosed is the maximum aggregate offering price of up to $50,000,000 for shares of common stock under the new sales agreement.
Material Changes
The material change reported is the execution of an Open Market Sale Agreement (the "Sales Agreement") with Jefferies LLC. Under this agreement, BlueLinx may issue and sell shares of its common stock from time to time through Jefferies as its sales agent in an "at the market" offering. The company has no obligation to sell any shares under this agreement.
Guidance, Outlook, and Risks
- Transaction Terms: Jefferies will act as sales agent on a commercially reasonable efforts basis. The company will pay Jefferies a cash commission of up to 3.0% of the gross proceeds from any sales.
- Termination: The offering will terminate upon the earlier of the sale of all shares, termination of the agreement, or the third anniversary of the effective date of the underlying Registration Statement (September 8, 2020).
- Legal Opinion: An opinion regarding the sale was delivered by Kilpatrick Townsend & Stockton LLP and is filed as an exhibit.
- Risks: The filing notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration or qualification.
Investor Verification Checklist
- Verify the current market price of BlueLinx common stock (Symbol: BXC) to assess the potential dilution impact of a $50 million offering.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific conditions regarding the timing and volume of potential sales.
- Confirm the status of the underlying shelf registration statement (File No. 333-234965) to ensure it remains effective.
- Monitor future filings to determine if and when the company elects to sell shares under this agreement.